| Name | Title | Contact Details |
|---|
The Permanente Medical Group was established in 1948 with seven original partners. Today, we are an integral part of Kaiser Permanente with the stability of more than 50 years serving the communities of Northern California. As the quality leader in
CTI Molecular Imaging Inc is a Knoxville, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CCS Medical Holdings Inc. is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Inspire Medical Systems, Inc. has developed the world`s first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient`s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition. Inspire therapy works inside your body, and with your natural breathing process. It might be right for you if you have been diagnosed with OSA, and can`t use or don`t get relief from CPAP/BiPAP.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.